Latest Prostate Specific Antigen News
Older men whose clinician was a physician trainee had substantially lower prostate-specific antigen (PSA) screening rates.
The proportion of biopsied men who have complications from the procedure rose from 14% to 18% from 2005 to 2014.
This includes less frequent screening and more restrictive biopsy referral criteria.
Differential effect of 2012 USPSTF recommendations for primary care providers, urologists.
Rate of unnecessary screening was 15.7% in men 65 years and older.
Prostate cancer is 1.4 times more likely to develop in those with a PSA level of 2.5 ng/mL or higher.
Equal serum prostate-specific antigen and prostate-specific antigen mass despite larger prostates.
A 50% or greater PSA decline at 15 days after start of treatment was associated with increased progression-free and overall survival.
Prostate-specific antigen density, total tumor length are significant predictors.
After, men undergoing prostate needle biopsy more likely to be diagnosed with high-risk disease.
Screening not linked to improved patient survival after transplant; may delay time to listing, transplant.
Researchers say they believe study findings support a hypothesis than ejaculation resulting from sexual intercourse might cause PSA bounce.
Men with a normal PSA upon repeat testing had a 78% lower risk of prostate cancer diagnosis than men with a second abnormal PSA result.
Only 4.5% of Medicare patients on active surveillance or watchful waiting for prostate cancer are monitored as closely as they should be.
The time to PSA progression in men with relapsing or locally advanced PCa was similar with intermittent and continuous androgen deprivation.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)